Incidence of anal cancer has already peaked among HIV-positive gay men; reductions can be achieved with expanded ART coverage and screening
Treatment with DAAs reduces the risk of mortality in the first 18 months after the completion of treatment
Switch from boosted protease inhibitor to dolutegravir reduces lipids in people with HIV at higher risk of heart disease
Boosted darunavir plus lamivudine matches three-drug regimen
European and US regulators approve AbbVie's new combo for all hepatitis C genotypes
Demand for access to NHS PrEP trial looks set to outstrip places
PrEP demand in England is rapidly accelerating – and most will want to join the trial
What marks out HIV controllers from others?
Why curing HIV may be like curing cancer – and may be as difficult
